Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis
Authors
Keywords
Chronic myeloid leukemia, Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib, Tyrosine kinase inhibitors, BCR-ABL tyrosine kinase, Omacetaxine
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 14, Issue 2, Pages 127-143
Publisher
Springer Nature
Online
2013-04-09
DOI
10.1007/s11864-013-0234-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How to Choose Frontline Therapy for Chronic Myelogenous Leukemia: So Many Drugs, Not So Many Patients
- (2017) Paul J. Shami Journal of the National Comprehensive Cancer Network
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells
- (2012) Dong Wang et al. BIOTECHNOLOGY LETTERS
- CML: the good, the better, and the difficult choices
- (2012) J. Cortes BLOOD
- Targeting of GSK3 promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells
- (2012) G. Reddiconto et al. BLOOD
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
- (2012) D. Marin et al. BLOOD
- Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide
- (2012) D. J. Goussetis et al. BLOOD
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- How I treat newly diagnosed chronic phase CML
- (2012) J. Cortes et al. BLOOD
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Selective elimination of leukemia stem cells: Hitting a moving target
- (2012) Leslie A. Crews et al. CANCER LETTERS
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Nilotinib-Associated Vascular Events
- (2012) Alfonso Quintás-Cardama et al. Clinical Lymphoma Myeloma & Leukemia
- Emerging Therapies in Chronic Myeloid Leukemia
- (2012) J. Gora-Tybor CURRENT CANCER DRUG TARGETS
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
- (2012) Richard A. van Etten et al. LEUKEMIA & LYMPHOMA
- Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009
- (2012) Yiming Chen et al. LEUKEMIA & LYMPHOMA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis
- (2012) Simona Soverini et al. PHARMACOGENOMICS
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
- (2011) G. V. Helgason et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia
- (2011) Yaoyu Chen et al. CELL CYCLE
- Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
- (2011) Meir Wetzler et al. CURRENT PHARMACEUTICAL DESIGN
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
- (2010) A. Kreutzman et al. BLOOD
- Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
- (2010) A. Haouala et al. BLOOD
- Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia
- (2010) Jorge Cortes et al. CANCER
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
- (2010) Bin Zhang et al. CANCER CELL
- Pleural effusions due to dasatinib
- (2010) Anupama G Brixey et al. CURRENT OPINION IN PULMONARY MEDICINE
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
- (2009) E. Jabbour et al. BLOOD
- Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
- (2009) A. Quintas-Cardama et al. BLOOD
- Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
- (2009) Michele Baccarani et al. BLOOD
- KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
- (2009) Y. Shiotsu et al. BLOOD
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
- (2009) Hagop M. Kantarjian et al. CANCER
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
- (2009) Hagop Kantarjian et al. CANCER
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
- (2009) F J Giles et al. LEUKEMIA
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
- (2008) A. Gontarewicz et al. BLOOD
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
- (2008) C M Lucas et al. LEUKEMIA
- PML targeting eradicates quiescent leukaemia-initiating cells
- (2008) Keisuke Ito et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More